Document Detail

Chemotherapy for the biliary tract cancers: moving toward improved survival time.
MedLine Citation:
PMID:  22328060     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The biliary tract carcinomas rank fifth in incidence among all gastrointestinal tumours. This group of tumours includes both cholangiocarcinoma and gallbladder carcinoma. Although surgery represents the main therapeutic option for these patients, both radiotherapy and chemotherapy could be used in a multidisciplinary approach. Several studies are currently available on the use of chemotherapy, including 5-fluorouracil, mitomycin C, methotrexate, doxorubicin and cisplatin or newer anticancer molecules, such as gemcitabine, capecitabine, oxaliplatin and irinotecan. However, the small sample size of most of these studies prevents generalization.
DISCUSSION: We reviewed the available data on both chemotherapy and targeted therapies for biliary carcinoma. By using conventional chemotherapy, a response rate ranging from 10% to 40% has been reported. Although encouraging data emerged with the use of targeted therapies, further efforts are needed to improve treatment options for patients with biliary tract cancer.
Adriana Romiti; Chiara D'Antonio; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Viola Barucca; Valeria Durante; Paolo Marchetti
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of gastrointestinal cancer     Volume:  43     ISSN:  1941-6636     ISO Abbreviation:  J Gastrointest Cancer     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-08-23     Completed Date:  2013-02-05     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  101479627     Medline TA:  J Gastrointest Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  396-404     Citation Subset:  IM    
Department of Oncology, Sant'Andrea Hospital, La Sapienza University, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Biliary Tract Neoplasms / drug therapy*,  mortality*
Survival Rate
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ten antibodies, six colors, twelve parameters: A multiparameter flow cytometric approach to evaluate...
Next Document:  Basal ganglia-premotor dysfunction during movement imagination in writer's cramp.